Science Explorer Back to mapMap
Discussion
Researcher · Abbott Fund · United States

Thomas D. Penning

Thomas D. Penning publishes mostly in Oncology, Organic Chemistry and Molecular Biology, on topics such as PARP inhibition in cancer therapy, Inflammatory mediators and NSAID effects and Asthma and respiratory diseases.

ORCID 0000-0003-2287-6735 OpenAlex
World rank
#1,175,587
of 7,710,434 ranked researchers
Rank in United States
#377,812
of 1,627,098
Works
94
Citations
7.4k
Citations per work
78.7
h-index
31
i10-index 50Top 11% in Oncology
Thomas D. Penning

What does Thomas D. Penning research?

Thomas D. Penning's work is mostly in Medicine (31%), Chemistry (16%), Biochemistry, Genetics and Molecular Biology (15%).

Everything else: 30 works · 31.8% of their workHealth Sciences: 30 works · 31.4% of their workMedicine: 30 works · 31.4% of their workOncology: 16 works · 17.1% of their workPharmacology: 8 works · 8.3% of their workPhysiology: 6 works · 6.0% of their workLife Sciences: 19 works · 20.7% of their workBiochemistry, Genetics and Molecular Biology: 14 works · 14.7% of their workMolecular Biology: 14 works · 14.7% of their workImmunology and Microbiology: 6 works · 6.0% of their workImmunology: 6 works · 6.0% of their workPhysical Sciences: 15 works · 16.1% of their workChemistry: 15 works · 16.1% of their workOrganic Chemistry: 15 works · 16.1% of their workTHEIR WORKThomas D. Penning94works
Life Sciences21%Physical Sciences16%Health Sciences31%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
  1. Everything else3031.8%
    1. Medicine3031.4%
    1. Biochemistry, Genetics and Molecular Biology1414.7%
    2. Immunology and Microbiology66.0%
    1. Chemistry1516.1%
  1. 1Oncology17% of their works
  2. 2Organic Chemistry16% of their works
  3. 3Molecular Biology15% of their works
  4. 4Pharmacology8% of their works
  5. 5Physiology6% of their works
  6. 6Immunology6% of their works

Research topics

Which keywords describe Thomas D. Penning's research?

The keywords of their largest research topics: Inflammation, Homologous Recombination, Cancer, Cancer Therapy, BRCA Mutation, PARP Inhibitors, Cyclooxygenase-2 Inhibitors and Prostaglandins.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 20 words, with their numbers
  1. Inflammation343 topics
  2. Homologous Recombination332 topics
  3. Cancer313 topics
  4. Cancer Therapy282 topics
  5. BRCA Mutation231 topic
  6. PARP Inhibitors231 topic
  7. Cyclooxygenase-2 Inhibitors151 topic
  8. Prostaglandins151 topic
  9. Allergic Diseases131 topic
  10. Asthma131 topic
  11. DNA Damage101 topic
  12. Repair101 topic
  13. Heterocyclic Compounds91 topic
  14. Medicinal Chemistry91 topic
  15. DNA81 topic
  16. Topoisomerases81 topic
  17. Cell Adhesion61 topic
  18. Integrins61 topic
  19. Cell Cycle51 topic
  20. p5351 topic

Where does Thomas D. Penning work?

Thomas D. Penning's main affiliation in the publication record is Abbott Fund, United States.

How many publications and citations does Thomas D. Penning have?

OpenAlex counts 94 works and 7,394 citations for Thomas D. Penning, an h-index of 31, ranking #1,175,587 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Thomas D. Penning. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.